	US 11,951,131 B2
	Anti-SLAMF7 chimeric antigen receptors
James N. Kochenderfer, Bethesda, MD (US); and Steven A. Feldman, Redwood City, CA (US)
Assigned to The United States of America, as represented by the Secretary, Department of Health and Human Services, Bethesda, MD (US)
Appl. No. 17/255,005
Filed by The United States of America, as represented by the Secretary,Department of Health and Human Services, Bethesda, MD (US)
PCT Filed Jun. 26, 2019, PCT No. PCT/US2019/039239 § 371(c)(1), (2) Date Dec. 22, 2020, PCT Pub. No. WO2020/009868, PCT Pub. Date Jan. 9, 2020.
Claims priority of provisional application 62/693,779, filed on Jul. 3, 2018.
Prior Publication US 2021/0260125 A1, Aug. 26, 2021
Int. Cl. A61K 35/17 (2015.01); A61P 35/00 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01)

CPC A61K 35/17 (2013.01) [A61P 35/00 (2018.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01)]

16 Claims

1. A nucleic acid comprising:

(a) a suicide gene; and

(b) a nucleotide sequence encoding a chimeric antigen receptor (CAR), wherein the CAR comprises a single chain comprising an antigen recognition domain, a transmembrane (TM) domain, and a T cell activation domain, wherein the CAR has antigenic specificity for signaling lymphocyte activating molecule F7 (SLAMF7), wherein the TM domain comprises a TM domain of CD8α or CD28, wherein the antigen recognition domain comprises the amino acid sequences of SEQ ID NOs: 1-6;

wherein the nucleotide sequence encoding the CAR is positioned 3′ of the suicide gene, and wherein the suicide gene is an inducible caspase 9 (IC9) gene.